The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index; 35 of the 52 sources its claims cite were checked for support.
Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters
Open accessAbstract
Selective serotonin reuptake inhibitors (SSRIs), widely used for anxiety and depression, are often criticized for their perceived similarity in efficacy to placebo treatments... Findings suggest shared neural pathways between SSRIs and placebos, possibly related to response expectancies.
Overview
CoChat Summary
## TL;DR
This perspective paper reviews the authors’ PET neuroimaging studies in social anxiety disorder (SAD) and argues that SSRI benefits are only partly pharmacological: expectancy effects, especially via dopamine signaling, account for much of the observed improvement. Across studies, SSRI and placebo responses shared some amygdala-related neural changes, but serotonin transporter occupancy alone did not track symptom improvement.
## Key findings
- In 72 SAD patients from three randomized, double-blind, placebo-controlled trials, both SSRI and placebo responders showed attenuation of anxiety-related amygdala activity in the left basolateral and right ventrolateral subregions, with no significant difference between SSRI and placebo responders; clinical improvement was comparable.
- In the deception study, overt escitalopram produced greater symptom improvement than covert escitalopram: the overt group had about twice the effect size (Cohen’s d = 2.24 vs. 1.13), and 50% vs. 14% showed clinically significant improvement; PET findings linked expectancy to dopamine transporter changes (p < 0.001, R = −0.61).
- In the serotonin-transporter PET analysis, average serotonin transporter occupancy was 78%, but occupancy did not correlate with social anxiety improvement, and symptom improvement did not correlate with escitalopram or metabolite blood concentrations.
- In the CBT combination study, escitalopram + CBT and placebo + CBT both improved symptoms, with LSAS-SR reductions of 37 and 24 points, respectively; longer-term outcomes at 15 months favored escitalopram + CBT (p = 0.03, Cohen’s d = 1.58 vs. 0.87).
## Methods
- Perspective/review paper synthesizing multiple neuroimaging studies by the authors in SAD; the paper explicitly says all studies are in the public domain and there are no secondary analyses.
- Studies discussed included PET imaging of amygdala activity, serotonin transporter binding, and dopamine transporter binding in SAD patients under SSRI, placebo, deception, and CBT conditions.
- Main analyses compared symptom outcomes and PET-derived neurochemical/neural changes across treatment groups, including randomized double-blind placebo-controlled trials and a deception design manipulating treatment expectations.
## Limitations
- The authors note that the deception study used only two of the four balanced-placebo conditions, because ethical and practical considerations prevented inclusion of the full design.
- They state that the CBT study was not designed to isolate CBT’s specific effects, and expectations were not manipulated in that study.
- Evident from the text: several conclusions come from a perspective paper summarizing prior studies rather than from one new primary dataset, and some findings are based on subsamples (for example, 27 PET participants and 24 completers in the CBT/PET study).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) PET scans of serotonin transporters in patients with social anxiety disorder, using the tracer [11C]-DASB, before treatment (left) and treatment effects (right). After treatment, an equally high average occupancy of serotonin transporters (altered binding) was observed with overt and covert SSRI treatment. No group differences were present before treatment. See Hjorth et al. (2021) for details. (b) Corresponding PET scans of dopamine transporters, using the tracer [11C]-PE2I, before treatment (left) and treatment effects in the putamen/pallidum (right). After treatment, a decrease in dopamine transporter availability was observed in the overt SSRI group, while increases were seen in the covert SSRI group. No group differences were present before treatment. See Hjorth et al. (2021) for details. (c) Percentage of responders and symptom improvement during treatment in the two groups as measured with the Liebowitz Social anxiety scale self-report (LSAS-SR) in the whole sample. See Faria et al. (2017) for details; *p < 0.05, **p < 0.01, ***p < 0.005.](https://figures.cochat.ai/paper-figures/a2124b64f6a34ae1af77095b78df9b9c/revisiting-the-ssri-vs-placebo-debate-in-the-treatment-of-social-anxiety-figure-2.jpg)
Verification
Claims the paper makes
28 Valid · 3 Not valid · 9 Not checked · 24 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“this action doesn't consistently correlate with symptom improvement (Cavanagh et al., 2006; Hjorth et al., 2021).”
§ Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters > Introduction
What the sources say
- Not checked — no full text of the sourcecites Cavanagh et al., 2006 source
- Supportedcites Hjorth et al., 2021 source
The Discussion reports that serotonin transporter (SERT) occupancy did not correlate with reduced social anxiety in this trial, despite differing clinical outcomes between treatment groups. It also notes that several molecular imaging studies have failed to find a relationship between SERT occupancy and clinical response to SSRIs. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Downstream effects—such as those on dopamine neurotransmission, implicated in approach-avoidance motivation—may also play a key role.”
§ Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters > Introduction
What the sources say
- Partly supportedcites Boureau and Dayan, 2011 sourceExperimental — accuracy not yet measured
The section ‘The Serotonergic System and Its Regulation of the Dopaminergic System’ (page unavailable) describes serotonin’s effects on dopamine release, and ‘Immediate Effects’ links dopamine to avoidance learning and antidepressant effects. The copy does not establish that downstream effects on dopamine play a key role in SSRI-responsive disorders specifically. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In particular, side effects associated with SSRIs can inadvertently reveal participants' group assignments, undermining the blind.”
§ Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters > Introduction
What the sources say
- Not matchedcites Chen et al., 2011, 2015
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites Hróbjartsson et al., 2014 sourceExperimental — accuracy not yet measured
The Introduction and Discussion address the consequences of patients knowing their treatment assignments, chiefly in complementary or alternative therapy trials. Searches for SSRIs, antidepressants, side effects, and adverse events found no passage saying that drug side effects reveal assignments or break the blind. (LLM, conf=0.73)
- Not checked — no full text of the sourcecites Margraf et al., 1991 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interactions between dopamine and serotonin signaling may be important for both anhedonia and heightened sensitivity to, and avoidance of, threatening stimuli (Boureau and Dayan, 2011).”
§ Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters > Introduction
What the sources say
- Partly supportedcites Boureau and Dayan, 2011 sourceExperimental — accuracy not yet measured
The Aversive Responses and Learned Effects sections discuss dopamine and serotonin in responses to threat and avoidance learning. The copy does not establish that their interactions are important for anhedonia or heightened sensitivity to threatening stimuli; those more specific parts of the claim remain unsupported. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies show that patient expectations about treatment effectiveness can significantly impact health outcomes (Mohamed Mohamed et al., 2020; Laferton et al., 2017; Bingel, 2020; Colloca et al., 2004).”
§ Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters > Introduction
What the sources say
- Partly supportedcites Mohamed Mohamed et al., 2020 sourceExperimental — accuracy not yet measured
The Introduction (p. 1) and Discussion/Table 3 of our copy do treat patient expectations as able to influence treatment outcomes ('PEs have the potential to influence outcomes regardless of the type of intervention'; 'Positive PEs prior to the treatment were shown to be associated with the pain intensity in both shorter and longer terms among CLBP individuals'), and the 'What's new' box states 'PEs positively influence PI and LF among CLBP patients'. However, the claim generalises this to 'health outcomes' at large, whereas our copy is confined to chronic low back pain patients receiving physiotherapy interventions and to pain intensity, functional status and HRQoL — and Section 3.5 reports mixed results (2 of 4 pain trials null, 3 of 6 function trials null, and the single HRQoL trial non-significant), so the broader 'health outcomes' reach is not supported. Likewise 'numerous studies show' overstates a review that synthesised only seven trials with a descriptive (non-quantitative) synthesis. (LLM, conf=0.75)
- Supportedcites Laferton et al., 2017 source
The Introduction says accumulating evidence links patients’ expectations to treatment outcomes across various medical conditions. The Conclusion also reports clinical intervention studies in which improving expectations led to improved health outcomes. As a review, this paper supports the claim by reporting those studies rather than conducting them itself. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites Bingel, 2020 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
29 more claims · 11 with their cited sources checked
Create a free account to see all 64 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 8
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Etkin, A., & Wager, T. D. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07030504 · Cited by 3,391 · cited 1×
“The amygdala is a crucial target for anxiolytic treatments due to its central role in fear processing, its connections with cortical regions involved in emotion regulation, and its heightened reactivity to emotional stimuli in patients with anxiety disorders (Etkin and Wager, 2007).”
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
The serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
Bingel, U., Wanigasekera, V., Wiech, K., Ni Mhuircheartaigh, R., Lee, M. C., Ploner, M., & Tracey, I. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001244 · Cited by 810
The Functional Neuroanatomy of the Placebo Effect
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.728 · Cited by 720
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680
Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.34 · Cited by 637
Overt versus covert treatment for pain, anxiety, and Parkinson's disease
Colloca, L., Lopiano, L., Lanotte, M., & Benedetti, F. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00908-1 · Cited by 552
Cited by
Guan, R., Wang, W., Dai, J., & Li, D. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1786210 · Cited by 2
Metadata
- Authors
- Furmark, T., Wahlstedt, K., & Faria, V.
- Affiliations
- Uppsala University (SE)
- Corresponding author
- Furmark, Tomas
- Venue
- Frontiers in Psychology
- Publisher
- Frontiers Media SA
- Published
- 2025-05-12
- Volume
- 16
- Pages
- 1531725-1531725
- ISSN
- 1664-1078 (ISSN-L)
- PMC
- PMC12104218
- OpenAlex
- W4410282128
- Cited by
- 1
- References
- 52
- Citations by year
- 2026: 1
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet
- Riksbankens Jubileumsfond
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- selective serotonin reuptake inhibitors, social anxiety disorder, placebo effect, expectancy effects, amygdala activity, dopamine signaling, serotonin transporter, monoamine transporters, cognitive behavioral therapy, fear processing, serotonin reuptake inhibition, treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters. https://app.cochat.ai/papers/10.3389/fpsyg.2025.1531725
- The paper
- Furmark, T., Wahlstedt, K., & Faria, V. (2025). Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2025.1531725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.